These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
663 related articles for article (PubMed ID: 33544838)
1. Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine. Bastard P; Michailidis E; Hoffmann HH; Chbihi M; Le Voyer T; Rosain J; Philippot Q; Seeleuthner Y; Gervais A; Materna M; de Oliveira PMN; Maia MLS; Dinis Ano Bom AP; Azamor T; Araújo da Conceição D; Goudouris E; Homma A; Slesak G; Schäfer J; Pulendran B; Miller JD; Huits R; Yang R; Rosen LB; Bizien L; Lorenzo L; Chrabieh M; Erazo LV; Rozenberg F; Jeljeli MM; Béziat V; Holland SM; Cobat A; Notarangelo LD; Su HC; Ahmed R; Puel A; Zhang SY; Abel L; Seligman SJ; Zhang Q; MacDonald MR; Jouanguy E; Rice CM; Casanova JL J Exp Med; 2021 Apr; 218(4):. PubMed ID: 33544838 [TBL] [Abstract][Full Text] [Related]
2. Molecular and immunological characterization of a DNA-launched yellow fever virus 17D infectious clone. Jiang X; Dalebout TJ; Lukashevich IS; Bredenbeek PJ; Franco D J Gen Virol; 2015 Apr; 96(Pt 4):804-814. PubMed ID: 25516543 [TBL] [Abstract][Full Text] [Related]
3. Activation and Kinetics of Circulating T Follicular Helper Cells, Specific Plasmablast Response, and Development of Neutralizing Antibodies following Yellow Fever Virus Vaccination. Sandberg JT; Ols S; Löfling M; Varnaitė R; Lindgren G; Nilsson O; Rombo L; Kalén M; Loré K; Blom K; Ljunggren HG J Immunol; 2021 Aug; 207(4):1033-1043. PubMed ID: 34321231 [TBL] [Abstract][Full Text] [Related]
4. Inherited IFNAR1 deficiency in otherwise healthy patients with adverse reaction to measles and yellow fever live vaccines. Hernandez N; Bucciol G; Moens L; Le Pen J; Shahrooei M; Goudouris E; Shirkani A; Changi-Ashtiani M; Rokni-Zadeh H; Sayar EH; Reisli I; Lefevre-Utile A; Zijlmans D; Jurado A; Pholien R; Drutman S; Belkaya S; Cobat A; Boudewijns R; Jochmans D; Neyts J; Seeleuthner Y; Lorenzo-Diaz L; Enemchukwu C; Tietjen I; Hoffmann HH; Momenilandi M; Pöyhönen L; Siqueira MM; de Lima SMB; de Souza Matos DC; Homma A; Maia MLS; da Costa Barros TA; de Oliveira PMN; Mesquita EC; Gijsbers R; Zhang SY; Seligman SJ; Abel L; Hertzog P; Marr N; Martins RM; Meyts I; Zhang Q; MacDonald MR; Rice CM; Casanova JL; Jouanguy E; Bossuyt X J Exp Med; 2019 Sep; 216(9):2057-2070. PubMed ID: 31270247 [TBL] [Abstract][Full Text] [Related]
5. Yellow fever vaccination elicits broad functional CD4+ T cell responses that recognize structural and nonstructural proteins. James EA; LaFond RE; Gates TJ; Mai DT; Malhotra U; Kwok WW J Virol; 2013 Dec; 87(23):12794-804. PubMed ID: 24049183 [TBL] [Abstract][Full Text] [Related]
6. Comparing immunogenicity and protective efficacy of the yellow fever 17D vaccine in mice. Ma J; Boudewijns R; Sanchez-Felipe L; Mishra N; Vercruysse T; Buh Kum D; Thibaut HJ; Neyts J; Dallmeier K Emerg Microbes Infect; 2021 Dec; 10(1):2279-2290. PubMed ID: 34792431 [TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model. Julander JG; Testori M; Cheminay C; Volkmann A Front Immunol; 2018; 9():1756. PubMed ID: 30116244 [TBL] [Abstract][Full Text] [Related]
8. Type III Interferon-Mediated Signaling Is Critical for Controlling Live Attenuated Yellow Fever Virus Infection Douam F; Soto Albrecht YE; Hrebikova G; Sadimin E; Davidson C; Kotenko SV; Ploss A mBio; 2017 Aug; 8(4):. PubMed ID: 28811340 [TBL] [Abstract][Full Text] [Related]
9. A chimeric yellow fever-Zika virus vaccine candidate fully protects against yellow fever virus infection in mice. Kum DB; Boudewijns R; Ma J; Mishra N; Schols D; Neyts J; Dallmeier K Emerg Microbes Infect; 2020; 9(1):520-533. PubMed ID: 32116148 [TBL] [Abstract][Full Text] [Related]
14. Autoantibodies Neutralizing Type I IFNs in the Bronchoalveolar Lavage of at Least 10% of Patients During Life-Threatening COVID-19 Pneumonia. Philippot Q; Fekkar A; Gervais A; Le Voyer T; Boers LS; Conil C; Bizien L; de Brabander J; Duitman JW; Romano A; Rosain J; Blaize M; Migaud M; Jeljeli M; Hammadi B; Desmons A; Marchal A; ; ; Mayaux J; Zhang Q; Jouanguy E; Borie R; Crestani B; Luyt CE; Adle-Biassette H; Sene D; Megarbane B; Cobat A; Bastard P; Bos LDJ; Casanova JL; Puel A J Clin Immunol; 2023 Aug; 43(6):1093-1103. PubMed ID: 37209324 [TBL] [Abstract][Full Text] [Related]
15. The early cellular signatures of protective immunity induced by live viral vaccination. Kohler S; Bethke N; Böthe M; Sommerick S; Frentsch M; Romagnani C; Niedrig M; Thiel A Eur J Immunol; 2012 Sep; 42(9):2363-73. PubMed ID: 22733156 [TBL] [Abstract][Full Text] [Related]
16. Japanese encephalitis virus/yellow fever virus chimera is safe and confers full protection against yellow fever virus in intracerebrally challenged mice. Yang H; Yang H; Li Z; Liu L; Wang W; He T; Fan F; Sun Y; Liu J; Li Y; Zeng X Vaccine; 2018 Apr; 36(18):2450-2455. PubMed ID: 29580643 [TBL] [Abstract][Full Text] [Related]
17. Pre-existing Autoantibodies Neutralizing High Concentrations of Type I Interferons in Almost 10% of COVID-19 Patients Admitted to Intensive Care in Barcelona. Solanich X; Rigo-Bonnin R; Gumucio VD; Bastard P; Rosain J; Philippot Q; Perez-Fernandez XL; Fuset-Cabanes MP; Gordillo-Benitez MÁ; Suarez-Cuartin G; Boza-Hernandez E; Riera-Mestre A; Parra-Martínez A; Colobran R; Antolí A; Navarro S; Rocamora-Blanch G; Framil M; Calatayud L; Corbella X; Casanova JL; Morandeira F; Sabater-Riera J J Clin Immunol; 2021 Nov; 41(8):1733-1744. PubMed ID: 34570326 [TBL] [Abstract][Full Text] [Related]
18. Autoantibodies against type I IFNs in patients with critical influenza pneumonia. Zhang Q; Pizzorno A; Miorin L; Bastard P; Gervais A; Le Voyer T; Bizien L; Manry J; Rosain J; Philippot Q; Goavec K; Padey B; Cupic A; Laurent E; Saker K; Vanker M; Särekannu K; ; ; ; ; ; ; ; García-Salum T; Ferres M; Le Corre N; Sánchez-Céspedes J; Balsera-Manzanero M; Carratala J; Retamar-Gentil P; Abelenda-Alonso G; Valiente A; Tiberghien P; Zins M; Debette S; Meyts I; Haerynck F; Castagnoli R; Notarangelo LD; Gonzalez-Granado LI; Dominguez-Pinilla N; Andreakos E; Triantafyllia V; Rodríguez-Gallego C; Solé-Violán J; Ruiz-Hernandez JJ; Rodríguez de Castro F; Ferreres J; Briones M; Wauters J; Vanderbeke L; Feys S; Kuo CY; Lei WT; Ku CL; Tal G; Etzioni A; Hanna S; Fournet T; Casalegno JS; Queromes G; Argaud L; Javouhey E; Rosa-Calatrava M; Cordero E; Aydillo T; Medina RA; Kisand K; Puel A; Jouanguy E; Abel L; Cobat A; Trouillet-Assant S; García-Sastre A; Casanova JL J Exp Med; 2022 Nov; 219(11):. PubMed ID: 36112363 [TBL] [Abstract][Full Text] [Related]
19. Mild COVID-19 despite autoantibodies against type I IFNs in autoimmune polyendocrine syndrome type 1. Meisel C; Akbil B; Meyer T; Lankes E; Corman VM; Staudacher O; Unterwalder N; Kölsch U; Drosten C; Mall MA; Kallinich T; Schnabel D; Goffinet C; von Bernuth H J Clin Invest; 2021 Jul; 131(14):. PubMed ID: 34061776 [TBL] [Abstract][Full Text] [Related]
20. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella. Nascimento Silva JR; Camacho LA; Siqueira MM; Freire Mde S; Castro YP; Maia Mde L; Yamamura AM; Martins RM; Leal Mde L; Vaccine; 2011 Aug; 29(37):6327-34. PubMed ID: 21640779 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]